title: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
abstract: OBJECTIVE
  To prospectively assess the reproductive outcome with a small bolus of hCG administered on the day of oocyte retrieval after ovulation induction with a GnRH agonist (GnRHa).
  
  
  METHODS
  Prospective, randomized trial.
  
  
  METHODS
  Three hospital-based IVF clinics.
  
  
  METHODS
  Three hundred five IVF/intracytoplasmic sperm injection patients after a GnRH antagonist protocol.
  
  
  METHODS
  Ovulation induction was performed with either 10,000 IU hCG or 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG on the day of oocyte retrieval.
  
  
  METHODS
  Reproductive outcome in the two groups.
  
  
  RESULTS
  No significant differences were seen regarding positive hCG/ET rate (48% and 48%), ongoing pregnancy rate (26% and 33%), delivery rate (24% and 31%), and rate of early pregnancy loss (21% and 17%) between the GnRHa and 10,000 IU hCG groups, respectively.
  
  
  CONCLUSIONS
  A small bolus of hCG in the GnRHa group secured the luteal phase, resulting in a comparable reproductive outcome in the two groups. However, a nonsignificant difference of 7% in delivery rates justifies further studies to refine the use of GnRHa for ovulation induction.
authors.affiliation: The Fertility Clinic, Skive Regional Hospital, Resenvej 25, 7800 Skive, Denmark. peter.humaidan@sygehusviborg.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Humaidan
authors.forename: Helle
authors.initials: H
authors.lastname: Ejdrup Bredkjaer
authors.forename: Lars Grabow
authors.initials: LG
authors.lastname: Westergaard
authors.forename: Claus
authors.initials: C
authors.lastname: Yding Andersen
mesh_terms: D000328:Adult; D001755:Blastocyst; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008183:Luteal Phase; D007986:Luteinizing Hormone / Q000097:blood; D054315:Oocyte Retrieval; D009865:Oocytes / Q000166:cytology; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D012102:Reproductive Control Agents / Q000008:administration & dosage*; D020554:Sperm Injections, Intracytoplasmic
chemical_list: D006063:Chorionic Gonadotropin; D012102:Reproductive Control Agents; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone